trademan1

trademan1

bouncing off the ultimate-ma with the oscillators bullish

trademan1

bouncing up off of support, looks like a bull flag breakout soon

trademan1

beat earnings estimates but gapped down, overreaction, now at support and the oscillators say its bullish, last gap down didn't seem to hurt the chart even on an earnings miss, so this time it should be even better for recovery

trademan1

buy on the dip, getting ready to bounce off the ultimate-ma

trademan1

bull flag breakout forming, measured move target

trademan1

double bottom reversal

trademan1

Inverted head and shoulders reversal

trademan1

Recently broke out above the ultimate-ma, finished a retest of the moving average, the awesome oscillator shows bullish divergence crossing over 0, t3-cci is green, gann swing is green, lots of facts say the chart is going up here. The recent price action is a small double bottom pattern forming, perhaps a measured move and more later.

trademan1

Amedica Becomes First to Receive FDA Clearance for Two-Level Cervical Interbody Cage Indications FDA Clearance Provides Additional Point of Differentiation in the Marketplace and a Valuable On-Label Treatment Option for Surgeons finance.yahoo.com Chart seems to have found support and is making a double bottom reversal.

trademan1

Bullish on this stock, the book value per share is 2.35 yet the price got scared down to 0.79 because management rescheduled earnings. Sort of looks like a double bottom should be formed once this anomaly is resolved.

trademan1

This seems to fit a pattern I am seeing with gapped down biotech stocks, buying to fill in the gap above. It's only as risky as the amount of shares bought, the stop and target levels are defined. Looks like to me it wants to go up, just broke above the peak from last week.

trademan1

Sophiris Bio had a Phase III drug trial test showing the drug was not effective and the market overreacted. The chart has a cash/share value (mrq) of $1.74, the float is 16.78 Million Shares (note today's volume alone is a large part of that), so with a tiny float, more cash per share on hand than the market price, and upcoming results for new Phase III results...

trademan1

Tetra Technologies beat analyst's Q4 earnings expectation with $0.09 versus $0.08 estimated. The chart is forming a double bottom reversal to go long on.

trademan1

The price action recently shows accumulation and there is a recent high volume bullish spike. A noted biotech investor has increased position in this company lately. There is an inverted head and shoulders reversal pattern on the chart.

trademan1

It gapped down in the past because they dropped one of their studies but the company has many other products in development. There are messages that the float has been bought up and funds and insiders are buying heavily for some event.

trademan1

Using the reward to risk tool I found a trade that is 3:1 or greater, considering the current last price, and nearby highs and lows. This does not mean the chart stops trending at my target of 50.67%, it probably has a larger run in store, but this gives me a risk to reward framework to work in and allows me to focus on only the best likely trades in front of me....

trademan1

Taking a recent swing low and swing high, the risk reward tool can measure potential profit to risk when stopped out and give the reward to risk ratio. Moving the mouse over the shaded area, here we see we can potentially make 375% while risking only 32.14% or in other words the ratio is 11.67, which is excellent. Any time one can use this tool to find a trade...

trademan1

This high beta stock that moves fast compared to the market has made a 61.8% fibonacci ("fib") retracement, and the fibonacci projection tool suggests a preliminary target around $4.